 Kevin Lillehei
Concepts (614)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pituitary Neoplasms | 29 | 2025 | 189 | 3.640 |
Why?
| | Adenoma | 23 | 2025 | 224 | 3.200 |
Why?
| | Brain Neoplasms | 48 | 2023 | 1255 | 3.010 |
Why?
| | Neurosurgical Procedures | 11 | 2025 | 195 | 2.070 |
Why?
| | Meningioma | 12 | 2022 | 93 | 1.970 |
Why?
| | Pituitary Gland | 11 | 2020 | 148 | 1.740 |
Why?
| | Central Nervous System Cysts | 3 | 2020 | 13 | 1.620 |
Why?
| | Glioblastoma | 18 | 2023 | 341 | 1.600 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2022 | 1038 | 1.380 |
Why?
| | Meningeal Neoplasms | 6 | 2022 | 101 | 1.300 |
Why?
| | Peripheral Nervous System Neoplasms | 6 | 2009 | 18 | 1.100 |
Why?
| | Central Nervous System Neoplasms | 7 | 2017 | 155 | 0.940 |
Why?
| | Glioma | 15 | 2020 | 399 | 0.910 |
Why?
| | Radiotherapy, Intensity-Modulated | 5 | 2016 | 137 | 0.860 |
Why?
| | Sphenoid Bone | 2 | 2016 | 17 | 0.860 |
Why?
| | Gliosarcoma | 5 | 2006 | 8 | 0.850 |
Why?
| | Cysts | 3 | 2020 | 113 | 0.760 |
Why?
| | Carmustine | 3 | 2017 | 50 | 0.720 |
Why?
| | Pituitary ACTH Hypersecretion | 2 | 2018 | 10 | 0.700 |
Why?
| | Evidence-Based Medicine | 1 | 2025 | 735 | 0.700 |
Why?
| | Cancer Vaccines | 5 | 2018 | 164 | 0.690 |
Why?
| | Neoplasms, Radiation-Induced | 4 | 2008 | 92 | 0.680 |
Why?
| | Hypopituitarism | 1 | 2020 | 15 | 0.660 |
Why?
| | Rhabdoid Tumor | 3 | 2010 | 99 | 0.640 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2019 | 123 | 0.600 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2016 | 210 | 0.600 |
Why?
| | Polyesters | 2 | 2017 | 77 | 0.560 |
Why?
| | Decanoic Acids | 1 | 2017 | 8 | 0.560 |
Why?
| | Bleomycin | 1 | 2019 | 248 | 0.560 |
Why?
| | Immunotherapy | 4 | 2006 | 627 | 0.560 |
Why?
| | Magnetic Resonance Imaging | 29 | 2022 | 3574 | 0.550 |
Why?
| | Adult | 72 | 2025 | 37715 | 0.530 |
Why?
| | Middle Aged | 73 | 2025 | 33226 | 0.520 |
Why?
| | Orbital Diseases | 1 | 2016 | 32 | 0.510 |
Why?
| | Aged | 54 | 2025 | 23803 | 0.480 |
Why?
| | Humans | 126 | 2025 | 136965 | 0.450 |
Why?
| | Male | 86 | 2025 | 67386 | 0.440 |
Why?
| | Female | 83 | 2025 | 73002 | 0.410 |
Why?
| | Brachial Plexus | 3 | 2007 | 28 | 0.400 |
Why?
| | Antineoplastic Agents | 5 | 2017 | 2111 | 0.390 |
Why?
| | Retrospective Studies | 28 | 2025 | 15536 | 0.390 |
Why?
| | Biomarkers, Tumor | 8 | 2017 | 1229 | 0.380 |
Why?
| | Dacarbazine | 7 | 2015 | 95 | 0.370 |
Why?
| | Skull Neoplasms | 4 | 2012 | 21 | 0.360 |
Why?
| | Chemoradiotherapy | 4 | 2015 | 227 | 0.360 |
Why?
| | Craniopharyngioma | 3 | 2020 | 73 | 0.350 |
Why?
| | Cisplatin | 3 | 1998 | 320 | 0.350 |
Why?
| | Immunotherapy, Adoptive | 5 | 1997 | 330 | 0.350 |
Why?
| | Extracellular Vesicles | 2 | 2024 | 147 | 0.340 |
Why?
| | Cautery | 1 | 2010 | 4 | 0.340 |
Why?
| | Antineoplastic Agents, Alkylating | 5 | 2013 | 69 | 0.330 |
Why?
| | Epithelioid Cells | 1 | 2010 | 8 | 0.330 |
Why?
| | Sella Turcica | 5 | 2018 | 17 | 0.330 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 2 | 2024 | 11 | 0.330 |
Why?
| | Monosomy | 1 | 2010 | 12 | 0.330 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2010 | 45 | 0.320 |
Why?
| | Astrocytoma | 5 | 2014 | 127 | 0.320 |
Why?
| | Neurosurgery | 2 | 2021 | 40 | 0.320 |
Why?
| | Combined Modality Therapy | 11 | 2016 | 1215 | 0.320 |
Why?
| | Hemangioma | 1 | 2009 | 43 | 0.310 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2010 | 126 | 0.300 |
Why?
| | Cadherins | 2 | 2024 | 201 | 0.300 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2010 | 309 | 0.300 |
Why?
| | Membrane Proteins | 2 | 2017 | 1151 | 0.290 |
Why?
| | Sarcoma, Ewing | 1 | 2009 | 97 | 0.280 |
Why?
| | Young Adult | 16 | 2025 | 13218 | 0.280 |
Why?
| | Spinal Nerve Roots | 2 | 2006 | 29 | 0.280 |
Why?
| | DNA Mutational Analysis | 3 | 2014 | 395 | 0.270 |
Why?
| | Fibromatosis, Abdominal | 1 | 2007 | 3 | 0.270 |
Why?
| | Tumor Cells, Cultured | 8 | 2017 | 942 | 0.270 |
Why?
| | Immunohistochemistry | 13 | 2011 | 1706 | 0.260 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2024 | 1382 | 0.260 |
Why?
| | Prolactinoma | 3 | 2019 | 13 | 0.260 |
Why?
| | Brachial Plexus Neuropathies | 1 | 2006 | 10 | 0.250 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2006 | 36 | 0.250 |
Why?
| | Diagnosis, Differential | 8 | 2010 | 1470 | 0.250 |
Why?
| | Oligonucleotides, Antisense | 1 | 2006 | 109 | 0.250 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 2 | 2017 | 11 | 0.240 |
Why?
| | Gonadotrophs | 5 | 2015 | 21 | 0.240 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 67 | 0.240 |
Why?
| | Ethanol | 1 | 2010 | 613 | 0.240 |
Why?
| | Rats, Inbred F344 | 7 | 2006 | 264 | 0.230 |
Why?
| | Oligonucleotide Array Sequence Analysis | 7 | 2015 | 756 | 0.230 |
Why?
| | Chordoma | 1 | 2024 | 13 | 0.220 |
Why?
| | Interleukin-2 | 6 | 1997 | 449 | 0.220 |
Why?
| | Neoplasms | 5 | 2013 | 2698 | 0.220 |
Why?
| | Treatment Outcome | 12 | 2020 | 10664 | 0.220 |
Why?
| | Hemangioblastoma | 1 | 2004 | 2 | 0.220 |
Why?
| | Postoperative Complications | 8 | 2018 | 2622 | 0.220 |
Why?
| | DNA-Binding Proteins | 2 | 2010 | 1472 | 0.220 |
Why?
| | Adolescent | 20 | 2020 | 21471 | 0.210 |
Why?
| | Osteoblasts | 1 | 2024 | 129 | 0.210 |
Why?
| | Neoplasms, Second Primary | 4 | 2012 | 113 | 0.210 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2004 | 141 | 0.210 |
Why?
| | Cell Movement | 2 | 2024 | 964 | 0.210 |
Why?
| | Neurologic Examination | 3 | 2019 | 119 | 0.210 |
Why?
| | Cauda Equina | 2 | 2004 | 6 | 0.200 |
Why?
| | Transcription Factors | 2 | 2010 | 1705 | 0.200 |
Why?
| | Inappropriate ADH Syndrome | 2 | 2018 | 8 | 0.200 |
Why?
| | Drug Implants | 3 | 2017 | 81 | 0.200 |
Why?
| | Postoperative Period | 3 | 2020 | 338 | 0.200 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2024 | 210 | 0.200 |
Why?
| | Neuroendocrine Tumors | 1 | 2024 | 105 | 0.200 |
Why?
| | Motor Cortex | 1 | 2003 | 61 | 0.190 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2000 | 171 | 0.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2015 | 1680 | 0.190 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2012 | 522 | 0.190 |
Why?
| | Pituitary Diseases | 3 | 2017 | 20 | 0.190 |
Why?
| | Pineal Gland | 1 | 2021 | 16 | 0.180 |
Why?
| | Pinealoma | 1 | 2021 | 10 | 0.180 |
Why?
| | Fistula | 1 | 2022 | 47 | 0.180 |
Why?
| | Prognosis | 10 | 2021 | 3931 | 0.180 |
Why?
| | Aspergillus | 2 | 2013 | 17 | 0.180 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 832 | 0.180 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2014 | 222 | 0.180 |
Why?
| | Frontal Bone | 2 | 2015 | 21 | 0.180 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2016 | 54 | 0.180 |
Why?
| | Follow-Up Studies | 8 | 2017 | 5048 | 0.170 |
Why?
| | Ki-67 Antigen | 4 | 2011 | 108 | 0.170 |
Why?
| | Neuropathology | 1 | 2020 | 4 | 0.170 |
Why?
| | Telepathology | 1 | 2020 | 4 | 0.170 |
Why?
| | Intracranial Hypotension | 1 | 2022 | 56 | 0.170 |
Why?
| | Prospective Studies | 11 | 2023 | 7512 | 0.170 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 667 | 0.170 |
Why?
| | Paraneoplastic Endocrine Syndromes | 1 | 2000 | 1 | 0.170 |
Why?
| | Esthesioneuroblastoma, Olfactory | 1 | 2000 | 1 | 0.170 |
Why?
| | Salivary Glands | 1 | 2020 | 33 | 0.160 |
Why?
| | Fluorescein | 1 | 2020 | 24 | 0.160 |
Why?
| | Reactive Oxygen Species | 2 | 2000 | 625 | 0.160 |
Why?
| | Survival Analysis | 7 | 2018 | 1278 | 0.160 |
Why?
| | Stereotaxic Techniques | 1 | 2020 | 39 | 0.160 |
Why?
| | Nose Neoplasms | 1 | 2000 | 23 | 0.160 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2000 | 25 | 0.160 |
Why?
| | Transcriptome | 3 | 2024 | 966 | 0.160 |
Why?
| | Radiosurgery | 3 | 2010 | 373 | 0.160 |
Why?
| | Tomography, X-Ray Computed | 12 | 2022 | 2654 | 0.160 |
Why?
| | Genes, Tumor Suppressor | 2 | 2017 | 80 | 0.150 |
Why?
| | Lung Neoplasms | 3 | 2013 | 2552 | 0.150 |
Why?
| | Neoplasm Grading | 2 | 2017 | 304 | 0.150 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 5 | 0.150 |
Why?
| | Dendritic Cells | 2 | 2023 | 483 | 0.150 |
Why?
| | Polyethylenes | 1 | 2018 | 14 | 0.150 |
Why?
| | Hemangioma, Cavernous | 1 | 1998 | 15 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2015 | 367 | 0.150 |
Why?
| | Aged, 80 and over | 12 | 2020 | 7559 | 0.150 |
Why?
| | Oligodendroglioma | 2 | 2014 | 13 | 0.150 |
Why?
| | ErbB Receptors | 4 | 2006 | 606 | 0.150 |
Why?
| | Endocrine Glands | 1 | 1998 | 16 | 0.150 |
Why?
| | International Educational Exchange | 1 | 2018 | 12 | 0.150 |
Why?
| | Stroke | 2 | 2021 | 1124 | 0.150 |
Why?
| | Sphenoid Sinus | 1 | 2018 | 11 | 0.150 |
Why?
| | Survival Rate | 6 | 2015 | 1882 | 0.150 |
Why?
| | Time Factors | 10 | 2011 | 6786 | 0.140 |
Why?
| | Antioxidants | 2 | 2000 | 588 | 0.140 |
Why?
| | Adenocarcinoma | 2 | 2004 | 869 | 0.140 |
Why?
| | Hyponatremia | 1 | 2018 | 42 | 0.140 |
Why?
| | Remission Induction | 1 | 2018 | 287 | 0.140 |
Why?
| | Cerebrovascular Disorders | 1 | 1998 | 96 | 0.140 |
Why?
| | Quinazolines | 2 | 2010 | 249 | 0.140 |
Why?
| | Mutation | 3 | 2014 | 3975 | 0.140 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2017 | 33 | 0.140 |
Why?
| | Prostheses and Implants | 1 | 2018 | 141 | 0.140 |
Why?
| | Rats | 8 | 2006 | 5544 | 0.140 |
Why?
| | Thalamic Diseases | 1 | 2017 | 3 | 0.130 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1747 | 0.130 |
Why?
| | Xanthomatosis | 1 | 2017 | 8 | 0.130 |
Why?
| | Desmosomes | 1 | 2017 | 21 | 0.130 |
Why?
| | Third Ventricle | 1 | 2017 | 17 | 0.130 |
Why?
| | Reoperation | 5 | 2020 | 567 | 0.130 |
Why?
| | Exophthalmos | 1 | 2016 | 18 | 0.130 |
Why?
| | Students, Medical | 1 | 2021 | 351 | 0.130 |
Why?
| | Cell Proliferation | 5 | 2015 | 2456 | 0.120 |
Why?
| | Brain Injuries | 1 | 2021 | 493 | 0.120 |
Why?
| | Cytokines | 2 | 2021 | 2070 | 0.120 |
Why?
| | Progesterone | 1 | 2017 | 255 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 1100 | 0.120 |
Why?
| | Receptors, Somatostatin | 1 | 2015 | 24 | 0.120 |
Why?
| | Neurothekeoma | 1 | 1995 | 4 | 0.120 |
Why?
| | Tibial Nerve | 1 | 1995 | 8 | 0.120 |
Why?
| | Occipital Lobe | 2 | 2006 | 22 | 0.120 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 73 | 0.120 |
Why?
| | Glycoproteins | 3 | 2012 | 356 | 0.120 |
Why?
| | Genes, p53 | 2 | 2011 | 70 | 0.120 |
Why?
| | Olfactory Pathways | 1 | 2015 | 36 | 0.120 |
Why?
| | Accidents, Aviation | 1 | 1994 | 5 | 0.110 |
Why?
| | Proteome | 2 | 2024 | 470 | 0.110 |
Why?
| | Antigens, Neoplasm | 2 | 2013 | 316 | 0.110 |
Why?
| | Karyotyping | 3 | 2008 | 103 | 0.110 |
Why?
| | Molecular Chaperones | 2 | 2013 | 193 | 0.110 |
Why?
| | Orbit | 1 | 2015 | 67 | 0.110 |
Why?
| | Biocompatible Materials | 1 | 2018 | 423 | 0.110 |
Why?
| | Neoplasm Invasiveness | 6 | 2014 | 495 | 0.110 |
Why?
| | Acromegaly | 1 | 2014 | 15 | 0.110 |
Why?
| | Cranial Irradiation | 1 | 1995 | 84 | 0.110 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 37 | 0.110 |
Why?
| | Intervertebral Disc Displacement | 2 | 1998 | 40 | 0.110 |
Why?
| | Ganglioglioma | 1 | 2014 | 34 | 0.110 |
Why?
| | Human Growth Hormone | 1 | 2014 | 48 | 0.110 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 25 | 0.110 |
Why?
| | Pituitary Gland, Posterior | 1 | 2013 | 2 | 0.110 |
Why?
| | Ganglioneuroma | 1 | 2013 | 2 | 0.110 |
Why?
| | Cerebral Hemorrhage | 2 | 1985 | 108 | 0.110 |
Why?
| | Seizures | 1 | 2017 | 427 | 0.100 |
Why?
| | Sarcoma, Alveolar Soft Part | 1 | 1993 | 6 | 0.100 |
Why?
| | Immune Tolerance | 2 | 2008 | 363 | 0.100 |
Why?
| | Aspergillosis | 1 | 2013 | 21 | 0.100 |
Why?
| | Child | 9 | 2022 | 21760 | 0.100 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 19 | 0.100 |
Why?
| | Telomerase | 3 | 2003 | 248 | 0.100 |
Why?
| | Joint Dislocations | 1 | 1993 | 49 | 0.100 |
Why?
| | Cell Division | 5 | 2012 | 789 | 0.100 |
Why?
| | Spinal Injuries | 1 | 1993 | 53 | 0.100 |
Why?
| | Neoplasm Transplantation | 3 | 2000 | 250 | 0.100 |
Why?
| | Patient Readmission | 1 | 2018 | 699 | 0.100 |
Why?
| | Dog Diseases | 1 | 2013 | 63 | 0.100 |
Why?
| | Muscles | 1 | 1993 | 327 | 0.100 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2009 | 83 | 0.100 |
Why?
| | Soft Tissue Neoplasms | 1 | 1993 | 112 | 0.090 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 1045 | 0.090 |
Why?
| | Craniotomy | 3 | 2015 | 76 | 0.090 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2012 | 57 | 0.090 |
Why?
| | Drug Resistance, Multiple | 2 | 2001 | 23 | 0.090 |
Why?
| | Spine | 1 | 1993 | 175 | 0.090 |
Why?
| | Curriculum | 1 | 2018 | 998 | 0.090 |
Why?
| | Skull | 2 | 2007 | 145 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 81 | 0.090 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3393 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 1114 | 0.090 |
Why?
| | Mitotic Index | 2 | 2011 | 23 | 0.090 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2010 | 7 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2809 | 0.090 |
Why?
| | Hyperthermia, Induced | 2 | 2002 | 116 | 0.090 |
Why?
| | Adenoma, Oxyphilic | 1 | 2010 | 7 | 0.080 |
Why?
| | Claudins | 1 | 2010 | 24 | 0.080 |
Why?
| | Tumor Burden | 4 | 2012 | 305 | 0.080 |
Why?
| | SMARCB1 Protein | 1 | 2010 | 30 | 0.080 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 11 | 0.080 |
Why?
| | Tanzania | 2 | 2020 | 58 | 0.080 |
Why?
| | Animals | 14 | 2013 | 36882 | 0.080 |
Why?
| | Lymphoma | 2 | 2008 | 209 | 0.080 |
Why?
| | Immunity, Cellular | 2 | 2003 | 267 | 0.080 |
Why?
| | Registries | 1 | 2017 | 2048 | 0.080 |
Why?
| | Neuroaspergillosis | 1 | 2008 | 2 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 323 | 0.080 |
Why?
| | Piperidines | 1 | 2010 | 207 | 0.070 |
Why?
| | Brain Abscess | 1 | 2008 | 10 | 0.070 |
Why?
| | Killer Cells, Lymphokine-Activated | 4 | 1993 | 12 | 0.070 |
Why?
| | Cytogenetics | 1 | 2008 | 10 | 0.070 |
Why?
| | Genetic Vectors | 2 | 2008 | 321 | 0.070 |
Why?
| | Cell Survival | 5 | 2015 | 1124 | 0.070 |
Why?
| | Arm Injuries | 1 | 1988 | 26 | 0.070 |
Why?
| | Prolactin | 3 | 2019 | 94 | 0.070 |
Why?
| | Dogs | 2 | 2013 | 399 | 0.070 |
Why?
| | Internship and Residency | 1 | 2018 | 1157 | 0.070 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 614 | 0.070 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2006 | 222 | 0.070 |
Why?
| | Transcription Factor Pit-1 | 2 | 2025 | 27 | 0.070 |
Why?
| | Steroidogenic Factor 1 | 2 | 2025 | 12 | 0.070 |
Why?
| | Wounds and Injuries | 1 | 1994 | 746 | 0.070 |
Why?
| | Drug Administration Schedule | 3 | 2010 | 749 | 0.070 |
Why?
| | Wounds, Penetrating | 1 | 1988 | 64 | 0.070 |
Why?
| | Radiotherapy Dosage | 3 | 2010 | 274 | 0.070 |
Why?
| | Interferon-beta | 1 | 2008 | 92 | 0.070 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2008 | 96 | 0.070 |
Why?
| | Mesenchymoma | 1 | 2007 | 8 | 0.070 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2007 | 17 | 0.070 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2007 | 12 | 0.070 |
Why?
| | Hematoma | 2 | 1985 | 52 | 0.070 |
Why?
| | Superoxide Dismutase | 2 | 2000 | 351 | 0.070 |
Why?
| | Scalp | 1 | 2007 | 35 | 0.070 |
Why?
| | Adenoviridae | 1 | 2008 | 194 | 0.070 |
Why?
| | Radiography | 3 | 2013 | 814 | 0.070 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 43 | 0.060 |
Why?
| | Blood Vessels | 1 | 1988 | 182 | 0.060 |
Why?
| | Neoplasm Staging | 4 | 2015 | 1352 | 0.060 |
Why?
| | Enophthalmos | 1 | 2006 | 2 | 0.060 |
Why?
| | Dexamethasone | 4 | 2012 | 359 | 0.060 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 457 | 0.060 |
Why?
| | Base Pair Mismatch | 1 | 2006 | 10 | 0.060 |
Why?
| | Hemangioma, Capillary | 1 | 2006 | 12 | 0.060 |
Why?
| | Child, Preschool | 5 | 2017 | 10952 | 0.060 |
Why?
| | Blepharoptosis | 1 | 2006 | 11 | 0.060 |
Why?
| | Epidermal Cyst | 1 | 2006 | 11 | 0.060 |
Why?
| | Immunoprecipitation | 1 | 2006 | 152 | 0.060 |
Why?
| | Injections, Subcutaneous | 1 | 2006 | 158 | 0.060 |
Why?
| | Imatinib Mesylate | 1 | 2006 | 75 | 0.060 |
Why?
| | Lymphoma, Follicular | 1 | 2006 | 41 | 0.060 |
Why?
| | Parietal Lobe | 1 | 2006 | 59 | 0.060 |
Why?
| | Brain Edema | 2 | 2004 | 61 | 0.060 |
Why?
| | Teratoma | 1 | 2007 | 116 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2008 | 297 | 0.060 |
Why?
| | Chest Pain | 1 | 2006 | 90 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 458 | 0.060 |
Why?
| | Karnofsky Performance Status | 3 | 2013 | 36 | 0.060 |
Why?
| | Vaccination | 2 | 2023 | 1428 | 0.060 |
Why?
| | Bone Diseases | 1 | 2006 | 63 | 0.060 |
Why?
| | Neoplasm, Residual | 2 | 2020 | 132 | 0.060 |
Why?
| | Ultrasonics | 2 | 2002 | 48 | 0.060 |
Why?
| | Benzamides | 1 | 2006 | 209 | 0.060 |
Why?
| | Wounds, Nonpenetrating | 1 | 1988 | 280 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2010 | 199 | 0.060 |
Why?
| | Lymphoma, B-Cell | 1 | 2006 | 110 | 0.060 |
Why?
| | Exons | 1 | 2006 | 350 | 0.060 |
Why?
| | Medulloblastoma | 1 | 2007 | 193 | 0.060 |
Why?
| | Cushing Syndrome | 1 | 2004 | 9 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2006 | 4276 | 0.060 |
Why?
| | Databases, Factual | 1 | 2010 | 1367 | 0.060 |
Why?
| | Calcitonin | 1 | 2004 | 27 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 1999 | 0.060 |
Why?
| | Myelography | 2 | 2022 | 37 | 0.050 |
Why?
| | Bevacizumab | 2 | 2015 | 135 | 0.050 |
Why?
| | Subarachnoid Space | 1 | 2004 | 8 | 0.050 |
Why?
| | von Hippel-Lindau Disease | 1 | 2004 | 11 | 0.050 |
Why?
| | S100 Proteins | 2 | 1995 | 37 | 0.050 |
Why?
| | Brain | 6 | 2017 | 2711 | 0.050 |
Why?
| | United States | 3 | 2017 | 14945 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 971 | 0.050 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 18 | 0.050 |
Why?
| | Radiotherapy | 1 | 2004 | 204 | 0.050 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2003 | 15 | 0.050 |
Why?
| | Piperazines | 1 | 2006 | 343 | 0.050 |
Why?
| | Craniocerebral Trauma | 1 | 1985 | 167 | 0.050 |
Why?
| | Proteomics | 2 | 2024 | 1106 | 0.050 |
Why?
| | Lymphocyte Activation | 3 | 1993 | 1134 | 0.050 |
Why?
| | Polymers | 2 | 1997 | 489 | 0.050 |
Why?
| | Quality of Life | 2 | 2013 | 2899 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 592 | 0.050 |
Why?
| | Image Enhancement | 1 | 2004 | 189 | 0.050 |
Why?
| | Dura Mater | 2 | 2000 | 34 | 0.050 |
Why?
| | Age Factors | 4 | 2014 | 3258 | 0.050 |
Why?
| | Pyrimidines | 1 | 2006 | 465 | 0.050 |
Why?
| | Disease Progression | 2 | 2021 | 2708 | 0.050 |
Why?
| | Incidence | 3 | 2003 | 2793 | 0.050 |
Why?
| | Neoplasm Proteins | 2 | 2003 | 427 | 0.050 |
Why?
| | Hydrocortisone | 1 | 2004 | 304 | 0.050 |
Why?
| | Transferases | 1 | 2022 | 33 | 0.050 |
Why?
| | Microtubule-Associated Proteins | 1 | 2003 | 194 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2024 | 483 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3556 | 0.050 |
Why?
| | DNA, Neoplasm | 3 | 2005 | 158 | 0.050 |
Why?
| | Thyrotropin | 5 | 1999 | 116 | 0.040 |
Why?
| | Spinal Cord | 1 | 2004 | 371 | 0.040 |
Why?
| | Public Opinion | 1 | 2021 | 66 | 0.040 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2022 | 62 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2003 | 791 | 0.040 |
Why?
| | Neuroimmunomodulation | 1 | 2000 | 65 | 0.040 |
Why?
| | Gene Amplification | 2 | 2015 | 102 | 0.040 |
Why?
| | Ethmoid Sinus | 1 | 2000 | 9 | 0.040 |
Why?
| | Frontal Sinus | 1 | 2000 | 5 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2021 | 165 | 0.040 |
Why?
| | Arginine Vasopressin | 1 | 2000 | 43 | 0.040 |
Why?
| | Visual Fields | 1 | 2020 | 90 | 0.040 |
Why?
| | Free Radicals | 1 | 2000 | 113 | 0.040 |
Why?
| | Immunosuppressive Agents | 2 | 2008 | 861 | 0.040 |
Why?
| | Pituitary Hormones | 1 | 1999 | 16 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2003 | 304 | 0.040 |
Why?
| | Dopamine Agonists | 1 | 2019 | 42 | 0.040 |
Why?
| | Gonadotropins, Pituitary | 2 | 2008 | 22 | 0.040 |
Why?
| | Chromosomes, Human, Pair 7 | 2 | 2005 | 18 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2007 | 842 | 0.040 |
Why?
| | Cerebral Cortex | 2 | 1998 | 433 | 0.040 |
Why?
| | Recurrence | 1 | 2023 | 1059 | 0.040 |
Why?
| | Depressive Disorder, Major | 1 | 2003 | 368 | 0.040 |
Why?
| | Up-Regulation | 2 | 2015 | 838 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 356 | 0.040 |
Why?
| | Infant | 2 | 2008 | 9392 | 0.040 |
Why?
| | Hot Temperature | 1 | 2001 | 391 | 0.040 |
Why?
| | Injections, Intralesional | 1 | 1998 | 35 | 0.040 |
Why?
| | Apoptosis | 2 | 2015 | 2542 | 0.040 |
Why?
| | Cerebral Veins | 1 | 1998 | 16 | 0.040 |
Why?
| | Biopsy | 2 | 2017 | 1083 | 0.040 |
Why?
| | Smooth Muscle Tumor | 1 | 1998 | 6 | 0.040 |
Why?
| | Sarcoma, Synovial | 1 | 1998 | 21 | 0.040 |
Why?
| | Catheters, Indwelling | 1 | 1998 | 89 | 0.040 |
Why?
| | Capacity Building | 1 | 2018 | 61 | 0.040 |
Why?
| | Leiomyosarcoma | 1 | 1998 | 28 | 0.040 |
Why?
| | Visual Acuity | 1 | 2020 | 361 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 162 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2018 | 75 | 0.030 |
Why?
| | Meningomyelocele | 1 | 1998 | 59 | 0.030 |
Why?
| | Preoperative Care | 2 | 2003 | 348 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2000 | 328 | 0.030 |
Why?
| | Drug Synergism | 1 | 1998 | 368 | 0.030 |
Why?
| | Cell Line | 3 | 2012 | 2855 | 0.030 |
Why?
| | Brain Diseases | 2 | 1998 | 144 | 0.030 |
Why?
| | Hypophysitis | 1 | 2017 | 3 | 0.030 |
Why?
| | Neuroectodermal Tumors, Primitive | 1 | 1997 | 11 | 0.030 |
Why?
| | Ventriculostomy | 1 | 2017 | 21 | 0.030 |
Why?
| | Leiomyoma | 1 | 1998 | 78 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2000 | 782 | 0.030 |
Why?
| | Hydrocephalus | 2 | 2017 | 106 | 0.030 |
Why?
| | Neuroendoscopy | 1 | 2017 | 23 | 0.030 |
Why?
| | Premenopause | 1 | 2017 | 130 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2017 | 116 | 0.030 |
Why?
| | Gonadotropins | 2 | 1999 | 40 | 0.030 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 206 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 1996 | 113 | 0.030 |
Why?
| | DNA Methylation | 1 | 2022 | 638 | 0.030 |
Why?
| | Granuloma | 1 | 2017 | 93 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2017 | 91 | 0.030 |
Why?
| | Postoperative Care | 1 | 1998 | 255 | 0.030 |
Why?
| | Biodegradation, Environmental | 1 | 1996 | 86 | 0.030 |
Why?
| | RNA, Messenger | 5 | 2011 | 2788 | 0.030 |
Why?
| | Cognition Disorders | 2 | 2015 | 502 | 0.030 |
Why?
| | Developing Countries | 1 | 2018 | 311 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 135 | 0.030 |
Why?
| | Immunophenotyping | 1 | 1997 | 323 | 0.030 |
Why?
| | Delayed-Action Preparations | 1 | 1997 | 173 | 0.030 |
Why?
| | Drainage | 1 | 2017 | 171 | 0.030 |
Why?
| | Endoscopy | 1 | 2018 | 310 | 0.030 |
Why?
| | Hyperostosis | 1 | 1995 | 5 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 925 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2005 | 1295 | 0.030 |
Why?
| | Signal Transduction | 3 | 2015 | 5047 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 329 | 0.030 |
Why?
| | Olfactory Nerve | 1 | 2015 | 3 | 0.030 |
Why?
| | Computational Biology | 1 | 2020 | 647 | 0.030 |
Why?
| | Lactic Acid | 1 | 1997 | 306 | 0.030 |
Why?
| | Faculty, Medical | 1 | 2018 | 287 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 214 | 0.030 |
Why?
| | Cysticercosis | 1 | 1995 | 3 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 34 | 0.030 |
Why?
| | Cells, Cultured | 3 | 2006 | 4136 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1441 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 56 | 0.030 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 1995 | 32 | 0.030 |
Why?
| | Audiometry | 1 | 1995 | 27 | 0.030 |
Why?
| | Nasal Cavity | 1 | 2015 | 52 | 0.030 |
Why?
| | Seat Belts | 1 | 1994 | 19 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 1995 | 44 | 0.030 |
Why?
| | Aircraft | 1 | 1994 | 22 | 0.030 |
Why?
| | Cerebral Arteries | 1 | 2015 | 58 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4542 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 103 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 46 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 1995 | 109 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 46 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 1993 | 1343 | 0.030 |
Why?
| | Personality Disorders | 1 | 2015 | 72 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 1046 | 0.030 |
Why?
| | Neuroimaging | 1 | 2016 | 261 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1998 | 746 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 226 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 177 | 0.030 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2015 | 171 | 0.030 |
Why?
| | Computer Simulation | 1 | 1998 | 982 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 279 | 0.030 |
Why?
| | Cohort Studies | 2 | 2017 | 5688 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 227 | 0.030 |
Why?
| | Paresis | 2 | 2007 | 30 | 0.030 |
Why?
| | Nervous System | 1 | 1993 | 67 | 0.030 |
Why?
| | Hypothyroidism | 2 | 1992 | 71 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 274 | 0.020 |
Why?
| | Models, Biological | 1 | 2000 | 1780 | 0.020 |
Why?
| | Phosphopyruvate Hydratase | 1 | 1992 | 26 | 0.020 |
Why?
| | Safety | 1 | 1994 | 343 | 0.020 |
Why?
| | Mice | 4 | 2012 | 17705 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1774 | 0.020 |
Why?
| | Neuroblastoma | 1 | 1993 | 160 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 436 | 0.020 |
Why?
| | Antibodies, Monoclonal | 4 | 2008 | 1412 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 859 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 1993 | 236 | 0.020 |
Why?
| | Fatal Outcome | 2 | 2007 | 302 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1993 | 193 | 0.020 |
Why?
| | G2 Phase | 1 | 2012 | 39 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2015 | 0.020 |
Why?
| | Vimentin | 1 | 1992 | 52 | 0.020 |
Why?
| | Lymphocytosis | 1 | 1992 | 11 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3266 | 0.020 |
Why?
| | Rhodamine 123 | 2 | 2001 | 5 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 122 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 158 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2014 | 1301 | 0.020 |
Why?
| | Lymphocytes | 1 | 1993 | 389 | 0.020 |
Why?
| | Cavernous Sinus | 1 | 2011 | 19 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2015 | 445 | 0.020 |
Why?
| | Cytoplasm | 1 | 2012 | 265 | 0.020 |
Why?
| | Skull Base | 1 | 2011 | 50 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1991 | 39 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 648 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 396 | 0.020 |
Why?
| | Intraoperative Care | 2 | 2003 | 55 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 162 | 0.020 |
Why?
| | Spleen | 1 | 1993 | 514 | 0.020 |
Why?
| | Algorithms | 1 | 1998 | 1700 | 0.020 |
Why?
| | Carcinoma | 1 | 2012 | 228 | 0.020 |
Why?
| | Retreatment | 1 | 2010 | 70 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 142 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 114 | 0.020 |
Why?
| | Camptothecin | 1 | 2010 | 114 | 0.020 |
Why?
| | Vision Disorders | 2 | 2007 | 143 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1993 | 384 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2010 | 157 | 0.020 |
Why?
| | Doxorubicin | 2 | 2001 | 338 | 0.020 |
Why?
| | Salvage Therapy | 1 | 2010 | 138 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 243 | 0.020 |
Why?
| | Hypogonadism | 1 | 1990 | 92 | 0.020 |
Why?
| | Ultrasonography | 2 | 1984 | 761 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2008 | 19 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 29 | 0.020 |
Why?
| | Kinetics | 1 | 1992 | 1635 | 0.020 |
Why?
| | Follicle Stimulating Hormone | 3 | 1999 | 244 | 0.020 |
Why?
| | Axillary Artery | 1 | 1988 | 12 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 420 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 2060 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 463 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 85 | 0.020 |
Why?
| | Subclavian Artery | 1 | 1988 | 28 | 0.020 |
Why?
| | CD3 Complex | 1 | 2008 | 104 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 783 | 0.020 |
Why?
| | Infant, Newborn | 3 | 1997 | 6051 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 857 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 33 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 1992 | 451 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3446 | 0.020 |
Why?
| | Rituximab | 1 | 2008 | 173 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1235 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 506 | 0.020 |
Why?
| | Methotrexate | 1 | 2008 | 250 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1251 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2008 | 382 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1992 | 526 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2007 | 433 | 0.020 |
Why?
| | Multigene Family | 1 | 2007 | 199 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1989 | 1085 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 519 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 137 | 0.020 |
Why?
| | Tretinoin | 1 | 2006 | 122 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2008 | 299 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 428 | 0.010 |
Why?
| | Coma | 1 | 1985 | 33 | 0.010 |
Why?
| | Cognition | 1 | 2013 | 1171 | 0.010 |
Why?
| | Action Potentials | 1 | 1988 | 491 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 357 | 0.010 |
Why?
| | Intracranial Pressure | 1 | 1985 | 57 | 0.010 |
Why?
| | Athletic Injuries | 1 | 1991 | 532 | 0.010 |
Why?
| | Blood-Brain Barrier | 1 | 1985 | 137 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 1041 | 0.010 |
Why?
| | Brain Concussion | 1 | 1991 | 575 | 0.010 |
Why?
| | Citrates | 1 | 1984 | 41 | 0.010 |
Why?
| | Sound | 1 | 1984 | 48 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2008 | 781 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2371 | 0.010 |
Why?
| | Blood | 1 | 1984 | 108 | 0.010 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2003 | 49 | 0.010 |
Why?
| | Injections | 1 | 1984 | 182 | 0.010 |
Why?
| | Antigens, CD | 1 | 2006 | 527 | 0.010 |
Why?
| | Trauma Centers | 1 | 1985 | 411 | 0.010 |
Why?
| | Heparin | 1 | 1984 | 250 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 2001 | 69 | 0.010 |
Why?
| | Cyclosporins | 1 | 2001 | 70 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 147 | 0.010 |
Why?
| | Pulsatile Flow | 2 | 1991 | 60 | 0.010 |
Why?
| | Verapamil | 1 | 2001 | 37 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1480 | 0.010 |
Why?
| | Ultrasonic Therapy | 1 | 2001 | 15 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 1985 | 627 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 166 | 0.010 |
Why?
| | Luteinizing Hormone | 2 | 1991 | 183 | 0.010 |
Why?
| | Lung | 1 | 2013 | 4035 | 0.010 |
Why?
| | Fushi Tarazu Transcription Factors | 1 | 1999 | 5 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 982 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2139 | 0.010 |
Why?
| | Brown-Sequard Syndrome | 1 | 1998 | 5 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2900 | 0.010 |
Why?
| | Syringomyelia | 1 | 1998 | 12 | 0.010 |
Why?
| | Pyramidal Tracts | 1 | 1998 | 30 | 0.010 |
Why?
| | Sensation Disorders | 1 | 1998 | 37 | 0.010 |
Why?
| | Therapy, Computer-Assisted | 1 | 1998 | 61 | 0.010 |
Why?
| | Thoracic Vertebrae | 1 | 1998 | 78 | 0.010 |
Why?
| | Iatrogenic Disease | 1 | 1998 | 66 | 0.010 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 48 | 0.010 |
Why?
| | Photography | 1 | 1998 | 100 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 206 | 0.010 |
Why?
| | Spinal Fractures | 1 | 1998 | 73 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1998 | 71 | 0.010 |
Why?
| | Cervical Vertebrae | 1 | 1998 | 139 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 1998 | 161 | 0.010 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 146 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 338 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 232 | 0.010 |
Why?
| | Lumbar Vertebrae | 1 | 1998 | 247 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2006 | 5733 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1999 | 506 | 0.010 |
Why?
| | Praziquantel | 1 | 1995 | 5 | 0.010 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 1995 | 36 | 0.010 |
Why?
| | Spinal Cord Injuries | 1 | 1998 | 213 | 0.010 |
Why?
| | RNA, Viral | 1 | 1998 | 682 | 0.010 |
Why?
| | Carotid Stenosis | 1 | 1995 | 96 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 1923 | 0.010 |
Why?
| | Nerve Compression Syndromes | 1 | 1992 | 21 | 0.010 |
Why?
| | Optic Chiasm | 1 | 1992 | 18 | 0.010 |
Why?
| | Unconsciousness | 1 | 1991 | 19 | 0.010 |
Why?
| | Amnesia | 1 | 1991 | 43 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1991 | 165 | 0.010 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 1992 | 53 | 0.010 |
Why?
| | Headache | 1 | 1992 | 146 | 0.010 |
Why?
| | Football | 1 | 1991 | 82 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 5812 | 0.010 |
Why?
| | Immunochemistry | 1 | 1989 | 14 | 0.000 |
Why?
| | Autoradiography | 1 | 1989 | 67 | 0.000 |
Why?
| | Histocytochemistry | 1 | 1989 | 79 | 0.000 |
Why?
| | Hyperthyroidism | 1 | 1989 | 23 | 0.000 |
Why?
| | Circadian Rhythm | 1 | 1991 | 474 | 0.000 |
Why?
| | Neutrophils | 1 | 1989 | 1264 | 0.000 |
Why?
| | Transcription, Genetic | 1 | 1989 | 1452 | 0.000 |
Why?
| | Intraoperative Period | 1 | 1982 | 57 | 0.000 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 1982 | 29 | 0.000 |
Why?
| | Arteriovenous Malformations | 1 | 1982 | 27 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1989 | 1975 | 0.000 |
Why?
| | Phenotype | 1 | 1989 | 3148 | 0.000 |
Why?
| | Gene Expression Regulation | 1 | 1989 | 2574 | 0.000 |
Why?
| | Pregnancy | 1 | 1992 | 6736 | 0.000 |
Why?
|
|
Lillehei's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|